ArticleEsophagus : official journal of the Japan Esophageal Society2026
Comparison of clinical and prognostic characteristics between superficial basaloid and conventional esophageal squamous carcinoma.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundSuperficial basaloid esophageal squamous cell carcinoma (SBSCC) is a rare variant of early esophageal squamous cell carcinoma. Its clinicopathological characteristics remain poorly defined. This study retrospectively investigates SBSCC cases treated with endoscopic submucosal dissection (ESD), comparing them to superficial conventional squamous cell carcinoma (SCSCC).
methodsPatients who underwent ESD for superficial esophageal squamous cell carcinoma at Nanjing Drum Tower Hospital between January 2014 and December 2019 were reviewed. Based on histopathological findings, cases were classified into SBSCC and SCSCC groups. Clinical, endoscopic, and pathological data were collected and outcomes analyzed.
resultsOut of 477 patients, 31 (6.5%) had SBSCC and 446 (93.5%) had SCSCC. SBSCC patients were more likely to be male (P = 0.027). No significant differences were found in age, smoking, alcohol use, tumor size, location, or ESD-related complications. However, SBSCC was associated with lower complete (74.2% vs. 91.5%; P = 0.006) and curative (58.1% vs. 75.6%; P = 0.031) resection rates, deeper invasion (P = 0.018), and more frequent vertical margin involvement (P = 0.010). Both overall survival (OS) and disease-free survival (DFS) were significantly lower in the SBSCC group compared to the SCSCC group (OS: 87.1% vs. 95.0%, P = 0.042; DFS: 76.7% vs. 94.2%, P < 0.05). Post-ESD surgery, chemoradiation, and recurrence were more frequent in SBSCC (P < 0.05). Multivariate analysis identified SBSCC as an independent risk factor for DFS (HR: 4.6; 95% CI 1.990-10.650; P < 0.001), while lymphovascular invasion and complete resection were significant for OS.
conclusionsESD is effective for both SBSCC and SCSCC with low complication rates. However, SBSCC presents with deeper invasion, lower curative resection rates, and worse DFS, highlighting the need for careful post-ESD management.
Indexed as
Identifiers
41410721What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.